<?xml version='1.0' encoding='utf-8'?>
<document id="9298257"><sentence text="Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin."><entity charOffset="129-140" id="DDI-PubMed.9298257.s1.e0" text="terfenadine" /><entity charOffset="145-153" id="DDI-PubMed.9298257.s1.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.9298257.s1.e0" e2="DDI-PubMed.9298257.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s1.e0" e2="DDI-PubMed.9298257.s1.e1" /></sentence><sentence text="The utility of primary human hepatocytes in the evaluation of drug-drug interactions is being investigated in our laboratories" /><sentence text=" Our initial approach was to investigate whether drug-drug interactions observed in humans in vivo could be reproduced in vitro using human hepatocytes" /><sentence text=" Two model drugs were studied: terfenadine and rifampin, representing compounds subjected to drug-drug interactions via inhibitory and induction mechanisms, respectively"><entity charOffset="31-42" id="DDI-PubMed.9298257.s4.e0" text="terfenadine" /><entity charOffset="47-55" id="DDI-PubMed.9298257.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.9298257.s4.e0" e2="DDI-PubMed.9298257.s4.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s4.e0" e2="DDI-PubMed.9298257.s4.e1" /></sentence><sentence text=" Terfenadine was found to be metabolized by human hepatocytes to C-oxidation and N-dealkylation products as observed in humans in vivo"><entity charOffset="1-12" id="DDI-PubMed.9298257.s5.e0" text="Terfenadine" /></sentence><sentence text=" Metabolism by human hepatocytes was found to be inhibited by drugs which are known to be inhibitory in vivo" /><sentence text=" Ki values for the various inhibitors were derived from the in vitro metabolism data, resulting in the following ranking of inhibitory potency: For the inhibition of C-oxidation, ketoconazole &gt; itraconazole &gt; cyclosporin approximately troleandomycin &gt; erythromycin &gt; naringenin"><entity charOffset="179-191" id="DDI-PubMed.9298257.s7.e0" text="ketoconazole" /><entity charOffset="194-206" id="DDI-PubMed.9298257.s7.e1" text="itraconazole" /><entity charOffset="209-220" id="DDI-PubMed.9298257.s7.e2" text="cyclosporin" /><entity charOffset="235-249" id="DDI-PubMed.9298257.s7.e3" text="troleandomycin" /><entity charOffset="252-264" id="DDI-PubMed.9298257.s7.e4" text="erythromycin" /><entity charOffset="267-277" id="DDI-PubMed.9298257.s7.e5" text="naringenin" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e0" e2="DDI-PubMed.9298257.s7.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e1" e2="DDI-PubMed.9298257.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e1" e2="DDI-PubMed.9298257.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e1" e2="DDI-PubMed.9298257.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e1" e2="DDI-PubMed.9298257.s7.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e1" e2="DDI-PubMed.9298257.s7.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e2" e2="DDI-PubMed.9298257.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e2" e2="DDI-PubMed.9298257.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e2" e2="DDI-PubMed.9298257.s7.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e2" e2="DDI-PubMed.9298257.s7.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e3" e2="DDI-PubMed.9298257.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e3" e2="DDI-PubMed.9298257.s7.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e3" e2="DDI-PubMed.9298257.s7.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e4" e2="DDI-PubMed.9298257.s7.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s7.e4" e2="DDI-PubMed.9298257.s7.e5" /></sentence><sentence text=" For the inhibition of N-dealkylation, itraconazole &gt; or = ketoconazole &gt; cyclosporin &gt; or = naringenin &gt; or = erythromycin &gt; or = troleandomycin"><entity charOffset="39-51" id="DDI-PubMed.9298257.s8.e0" text="itraconazole" /><entity charOffset="59-71" id="DDI-PubMed.9298257.s8.e1" text="ketoconazole" /><entity charOffset="74-85" id="DDI-PubMed.9298257.s8.e2" text="cyclosporin" /><entity charOffset="93-103" id="DDI-PubMed.9298257.s8.e3" text="naringenin" /><entity charOffset="111-123" id="DDI-PubMed.9298257.s8.e4" text="erythromycin" /><entity charOffset="131-145" id="DDI-PubMed.9298257.s8.e5" text="troleandomycin" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e0" e2="DDI-PubMed.9298257.s8.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e1" e2="DDI-PubMed.9298257.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e1" e2="DDI-PubMed.9298257.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e1" e2="DDI-PubMed.9298257.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e1" e2="DDI-PubMed.9298257.s8.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e1" e2="DDI-PubMed.9298257.s8.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e2" e2="DDI-PubMed.9298257.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e2" e2="DDI-PubMed.9298257.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e2" e2="DDI-PubMed.9298257.s8.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e2" e2="DDI-PubMed.9298257.s8.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e3" e2="DDI-PubMed.9298257.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e3" e2="DDI-PubMed.9298257.s8.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e3" e2="DDI-PubMed.9298257.s8.e5" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e4" e2="DDI-PubMed.9298257.s8.e4" /><pair ddi="false" e1="DDI-PubMed.9298257.s8.e4" e2="DDI-PubMed.9298257.s8.e5" /></sentence><sentence text=" Rifampin induction of CYP3A, a known effect of rifampin in vivo, was also reproduced in primary human hepatocytes"><entity charOffset="1-9" id="DDI-PubMed.9298257.s9.e0" text="Rifampin" /><entity charOffset="48-56" id="DDI-PubMed.9298257.s9.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.9298257.s9.e0" e2="DDI-PubMed.9298257.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s9.e0" e2="DDI-PubMed.9298257.s9.e1" /></sentence><sentence text=" Induction of CYP3A4, measured as testosterone 6 beta-hydroxylation, was found to be dose-dependent, treatment duration-dependent, and reversible"><entity charOffset="34-46" id="DDI-PubMed.9298257.s10.e0" text="testosterone" /></sentence><sentence text=" The induction effect of rifampin was observed in hepatocytes isolated from all 7 human donors studied, with ages ranging from 1"><entity charOffset="25-33" id="DDI-PubMed.9298257.s11.e0" text="rifampin" /></sentence><sentence text="7 to 78 years" /><sentence text=" To demonstrate that the rifampin-induction of testosterone 6 beta-hydroxylation could be generalized to other CYP3A4 substrates, we evaluated the metabolism of another known substrate of CYP3A4, lidocaine"><entity charOffset="25-33" id="DDI-PubMed.9298257.s13.e0" text="rifampin" /><entity charOffset="47-59" id="DDI-PubMed.9298257.s13.e1" text="testosterone" /><entity charOffset="196-205" id="DDI-PubMed.9298257.s13.e2" text="lidocaine" /><pair ddi="false" e1="DDI-PubMed.9298257.s13.e0" e2="DDI-PubMed.9298257.s13.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s13.e0" e2="DDI-PubMed.9298257.s13.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s13.e0" e2="DDI-PubMed.9298257.s13.e2" /><pair ddi="false" e1="DDI-PubMed.9298257.s13.e1" e2="DDI-PubMed.9298257.s13.e1" /><pair ddi="false" e1="DDI-PubMed.9298257.s13.e1" e2="DDI-PubMed.9298257.s13.e2" /></sentence><sentence text=" Dose-dependent induction of lidocaine metabolism by rifampin is observed"><entity charOffset="29-38" id="DDI-PubMed.9298257.s14.e0" text="lidocaine" /><entity charOffset="53-61" id="DDI-PubMed.9298257.s14.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.9298257.s14.e0" e2="DDI-PubMed.9298257.s14.e0" /><pair ddi="false" e1="DDI-PubMed.9298257.s14.e0" e2="DDI-PubMed.9298257.s14.e1" /></sentence><sentence text=" Our results suggest that primary human hepatocytes may be a useful experimental system for preclinical evaluation of drug-drug interaction potential during drug development, and as a tool to evaluate the mechanism of clinically observed drug-drug interactions" /><sentence text="" /></document>